ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma

CHARLOTTESVILLE, Va. — ZielBio, Inc., a clinical-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, today announced that the U.S.

Related Keywords

United States ,Kimberly Kelly ,Zielbio Inc ,Drug Administration ,Orphan Drug Designation ,Drug Designation ,Biotechnology ,Ceo ,Drug Discovery ,Infectious Causes Of Cancer ,Medical Specialties ,Medicine ,Merger And Acquisition ,Metastasis ,Bile Duct ,Cholangiocarcinoma ,Hepatology ,